Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.61 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19583065 | 0.86 | SLC29A1 (0.76) | SLC29A1NR2F2ADORA3 | |
| SCHEMBL1795030 | 0.85 | SLC29A1 (0.64) | SLC29A1ADORA3 | |
| SCHEMBL17865918 | 0.85 | SLC29A1 (0.62) | SLC29A1ADORA3 | |
| SCHEMBL20008060 | 0.84 | NR2F2 (0.54) | SLC29A1NR2F2CCNA2CDK2CDK5 | |
| SCHEMBL1796246 | 0.80 | SLC29A1 (0.60) | SLC29A1ADORA3 | |
| SCHEMBL10186161 | 0.80 | SLC29A1 (0.60) | SLC29A1ADORA3 | |
| SCHEMBL17875220 | 0.80 | SLC29A1 (0.60) | SLC29A1ADORA3 | |
| SCHEMBL13467483 | 0.79 | SLC29A1 (0.76) | SLC29A1 | |
| SCHEMBL19582977 | 0.79 | SLC29A1 (0.76) | SLC29A1 | |
| SCHEMBL1796043 | 0.79 | SLC29A1 (0.63) | SLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | MILLENNIUM PHARMACEUTICALS, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086785-A1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES | TYMP, TYMS, PPA1 | SLC29A1 1761/4885NR2F2 2928/4885CCNA2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.